HIT Consultant May 23, 2024
Fred Pennic

What You Should Know:

– Tempus AI, a leader in artificial intelligence (AI)-powered precision medicine, filed with the Securities and Exchange Commission (SEC) on Monday to raise up to $100M in an initial public offering (IPO). Industry analysts, however, believe this figure might be a placeholder, with the actual target amount closer to $600M.

– Founded in 2015 and headquartered in Chicago, Illinois, Tempus AI reported $562M in revenue for the fiscal year ending March 31, 2024.

Unlocking the Power of Precision Medicine

The company plans to list on the Nasdaq under the ticker symbol TEM. Notably, Tempus AI initially filed confidentially for the IPO on September 1, 2021. They also rebranded from Tempus Labs to Tempus AI...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: AI (Artificial Intelligence), Investments, Pharma / Biotech, Precision Medicine, Technology, Trends
Related Articles:
Getting started with AI agents (part 1): Capturing processes, roles and connections
Unlocking The Genetic Code: AI Reveals New Insights Into Psychiatric Disorders
Amazon Increases Total Investment in AI Startup Anthropic to $8 Billion
HIMSSCast: Care provider or tool? When and why patients like AI
Amazon doubles down on Anthropic, positioning itself as a key player in the AI arms race

Share This Article